Compare ASYS & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASYS | SLN |
|---|---|---|
| Founded | 1981 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 88 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.5M | 300.9M |
| IPO Year | 2006 | N/A |
| Metric | ASYS | SLN |
|---|---|---|
| Price | $18.80 | $10.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | 531.0K | ★ 559.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $79,364,000.00 | N/A |
| Revenue This Year | $2.82 | N/A |
| Revenue Next Year | $18.75 | N/A |
| P/E Ratio | $208.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.30 | $4.19 |
| 52 Week High | $25.71 | $11.06 |
| Indicator | ASYS | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 71.89 |
| Support Level | $17.48 | $5.87 |
| Resistance Level | $24.70 | N/A |
| Average True Range (ATR) | 2.11 | 0.80 |
| MACD | -0.25 | 0.37 |
| Stochastic Oscillator | 6.88 | 85.24 |
Amtech Systems Inc provides equipment, consumables and services for semiconductor device packaging, wafer production and device fabrication. Its products are used to fabricate and package GPUs for AI applications, SiC and Si power devices, and other optical, analog and digital devices, and are sold to semiconductor packaging, electronic assembly and device fabrication companies. It operates through two segments: Thermal Processing Solutions, which includes conveyorized reflow equipment, high-temperature conveyorized furnaces and diffusion furnaces with maximum revenue; and Semiconductor Fabrication Solutions, which includes consumables, equipment and services for wafer polishing, dicing and cleaning. The majority of revenue is derived from the United States.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.